Core Insights - Lantheus Holdings reported Q3 CY2025 results with revenue of $384 million, exceeding market expectations by 5.2% and showing a year-on-year growth of 1.4% [1][6] - The company raised its full-year revenue guidance to $1.5 billion, which is 1.1% above analysts' estimates, while maintaining its Adjusted EPS guidance at $5.58 [1][6] - Despite revenue exceeding expectations, the market reacted negatively due to lower operating margins and significant leadership changes [3] Financial Performance - Revenue: $384 million vs analyst estimates of $365 million, representing a 1.4% year-on-year growth [6] - Adjusted EPS: $1.27, in line with analyst estimates [6] - Adjusted EBITDA: $125 million, with a margin of 32.5%, beating analyst estimates of $113.7 million [6] - Operating Margin: 11.4%, a significant decrease from 35.3% in the same quarter last year [6] - Market Capitalization: $3.65 billion [6] Strategic Outlook - Management expects stable, low single-digit volume growth for PSMA PET products, countered by price compression and 340B pricing resets [4] - Anticipated launch of a new F-18 PSMA PET formulation, which could increase batch size by approximately 50% [4] - Focus on integrating recent acquisitions and navigating a competitive regulatory landscape [4][5] Management Commentary - Management attributed the quarter's results to pricing discipline in the prostate cancer franchise and operational integration of recent acquisitions [5] - CEO Brian Markison noted ongoing pricing stabilization and disciplined commercial execution as key factors for performance [3][5]